Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT

NCT04543188 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04543188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
January 8, 2021
Completion date
March 20, 2024
Enrollment
65 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, brain neoplasms, primary, carcinoma, non-small-cell lung, malignant melanoma, malignant neoplasms